27 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
The AI Race Gets Litigious https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001 Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077 Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
Top Research Reports for NVIDIA, Visa & Amgen https://www.zacks.com/commentary/2232860/top-research-reports-for-nvidia-visa-amgen?cid=CS-ZC-FT-research_daily-2232860 Feb 28, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V) and Amgen Inc. (AMGN).
Where Are Biotech ETFs Headed After Q4 Earnings? https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390 Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
PBYI vs. AMGN: Which Stock Should Value Investors Buy Now? https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2224255 Feb 09, 2024 - PBYI vs. AMGN: Which Stock Is the Better Value Option?
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4668054-amgen-inc-amgn-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Feb 06, 2024 - Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q4 2023 Earnings Conference Call February 6, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway -...
Amgen (AMGN) Reports Q4 Earnings: What Key Metrics Have to Say https://www.zacks.com/stock/news/2222222/amgen-amgn-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2222222 Feb 06, 2024 - Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113 Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511 Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.

Pages: 123

Page 1>